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Diabetic retinopathy (DR) scores have two funda-
mental objectives: (1) detecting DR complications
and their severity and (2) predicting the risk of
progression to DR complications when they are not
yet present. Detecting complications is the easiest
part as it only requires to properly evaluate the
existing situation such as finding new vessels or
an edema. On the contrary, predicting the risk
of progression is the most challenging part as it
involves predicting the future.
Over the last century, the Airlie house classifica-
tion group and later the Early Treatment Diabetic
Retinopathy Study Research (ETDRS) group have
done an outstanding work, even with the current
standard, to create and improve a scoring to be
used to predict the risk of DR progression before
the occurrence of complications.[1] Not all diseases
and complications can be predicted with the explo-
ration tools available. For example, the occurrence
of diabetic macular edema cannot yet be appropri-
ately predicted. Conversely, proliferative DR might
be predicted based on the signs seen on fundus
examination or, even better, on fundus photos.[1]
The ETDRS group has done a very precise step-
by-step work, evaluating not only the value of the
signs but also the reproducibility of their evaluation,
to identify the most suitable signs. Their choices
were also based on pragmatism. They did not
have all the currently available imaging modalities,
so they have mainly used 7-field fundus photos
covering for that time a satisfactory wide surface
of the fundus. Eventually, fluorescein angiography
has been found to be slightly more powerful than
standard photos. However, as it is an invasive
technique, the extra power supplied has not been
considered justified given the treatments available
at that time.[2] The diabetic retinopathy severity
scale (DRSS) and its simplified versions have finally
become the gold standard for evaluating DR in
clinical studies and for treating patients.
DR pathophysiology is better known today and it
is obvious that, before the occurrence of prolifera-
tion, fundus signs act as surrogates for diabetes-
related changes: deep hemorrhages are signs
of capillary non-perfusion that leads to ischemia
and vascular endothelial growth factor (VEGF)
secretion, while venous beading is a feature of
vessel impregnation with VEGF for example. Some
hemorrhages may eventually disappear over time
despite persistent non-perfusion but if the non-
perfusion area expands, new hemorrhages appear.
Therefore, the higher the extand of hemorrhages
is, the more new non-perfusion areas occur, and
the higher the risk of progression to prolifera-
tion is. It should be noted that these signs do
not correspond to the disease itself (i.e. retinal
héamorrahges per se are not the problem), but
are used to estimate the risk of DR progression to
its complicated forms. The DRSS and its variants
have been used for so long that over time many
clinicians have ended up merging these surrogate
signs with their meaning and the disease itself.
Thus, a reduction in hemorrhages has become the
equivalent of DR improvement. This might have
been acceptable as far as there was no mean to
dissociate disease progression and its surrogate
signs.
Intravitreal injections, in particular anti-VEGF
agents, have since been developed and used
for the treatment of diabetic macular edema. As
expected from an effective anti-angiogenic agent,
anti-VEGF drugs have been shown to be able to
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control new vessels in DR eyes. More interestingly,
it has also been shown that the DRSS score based
on color fundus photos could improve after anti-
VEGF intravitreal injections.[3, 4] For these reasons,
they have immediately been labeled as agents
improving DR. In case of regression of a complica-
tion of DR, including new vessels or edema, it may
be legitimate to call it DR improvement. However, in
case of reduction in signs of non-complicated DR,
this can only be acceptable if the risk of progres-
sion is proportionally reduced. In other words, if,
after anti-VEGF injection, the ETDRS-DRSS fundus
photo score decreases from 53, that is, severe
non-proliferative diabetic retinopathy (NPDR), to
35, that is, mild NPDR, the risk of progression to
proliferative DR during the year should decrease
from > 50% to < 10%, and it should evolve at least
as anymild NPDR that is likely to progress to severe
NPDR usually several years thereafter.
Data on DR evolution after anti-VEGF treatment
are limited but the reported series tend to sug-
gest that anti-VEGF intravitreal injections clear the
fundus from hemorrhages and signs of vessel
impregnation with VEGF without eliminating the
risks of neovascularization shortly after treatment
discontinuation.[5] This may indicate that despite
a DRSS score improvement, ischemia persists.
To explore this assumption, we have conducted
two successive studies evaluating retinal perfu-
sion after three anti-VEGF injections. In the first
study based on fluorescein angiography, no vessel
reperfusion was found despite an improved DRSS
score on color photos. Indeed, even after this short
treatment, new vessels, when present, regressed
partly or totally. Fundus signs also improved in
others. Then, the DRSS score improved by at
least one stage in 61% of eyes. Meanwhile, in
our study based on ultrawide-field fluorescein
angiography, no significant reperfusion of arteri-
oles or venules was observed in or around the
non-perfusion areas.[6] In the second study, using
a similar method but based on wide-field OCT
angiography, we found that despite a rapid DRSS
score improvement after anti-VEGF treatment, no
reperfusion occurred, including at the capillary
level.[7] Thus, our two studies have shown that
the DRSS score can improve in the absence of
reperfusion.
It is now the time to question the fundus-based
evaluation of DR after intravitreal injections. When
after intravitreal injection a severe NPDR (score
53 ETDRS-DRSS) changes its appearance to the
one of a mild NPDR (score 35) on fundus pho-
tography but continue to have the non-perfusion
of a score 53, will it evolve as a mild NPDR
or as a severe NPDR? If one considers that the
non-perfusion is the cause of ischemia and VEGF
production leading to proliferation, unless other
mechanisms are involved, the evolution should be
closer to the evolution of a severe NPDR. This
substantial doubt on the value of fundus-based
ETDRS-DRSS scores invalidates relying only on
color fundus for grading NPDR after intravitreal
injections.
Waiting more data or a new method for assess-
ing the risk of progression available, what may be
the practical effects of such an uncertainty on the
post-injection value of the ETDRS-DRSS scores?
In clinical practice, if the injections are continued
with short enough intervals, they may prevent
any complications, but if they are discontinued,
to be on the safe side, regardless of the fundus
appearance, the risk should be considered the
highest measured during the medical history of
the eye and the follow-up should be decided
accordingly. In some cases, OCT angiography or
fluorescein angiography may also help to reeval-
uate the status of retinal perfusion. In upcoming
clinical trials on this topic, it would be safe to
include as much as possible multimodal imaging
to compile data and also to be able to provide
information required by the updated standards
when they will end. We can indeed hope that
in the forthcoming years, we will better under-
stand with which modality and how we should
evaluate DR for eyes treated by intravitreal injec-
tions. More generally, regardless of injections,
isn’t it time to try to switch from the historical
classification of DR to new modalities using the
best available modern images and all available
data?
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